Dare Bioscience (DARE) director receives 10,000 stock options at $2.03 strike

Rhea-AI Filing Summary

Dare Bioscience, Inc. director Jessica D. Grossman received a grant of stock options covering 10,000 shares of common stock. The options have an exercise price of $2.03 per share and expire on June 11, 2036.

According to the terms, the option will vest in full on the earlier of the first anniversary of the grant date or immediately before the company’s first annual stockholder meeting after the grant date, as long as she continues serving as a director. The options also become fully exercisable upon a change in control of the company. Following this grant, she holds 10,000 stock options directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Grossman Jessica D.

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	10,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 10,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 10,000 options Exercise price: $2.03 per share Expiration date: June 11, 2036 +2 more

5 metrics

Options granted 10,000 options Stock option grant to director Jessica D. Grossman

Exercise price $2.03 per share Strike price for the 10,000 stock options

Expiration date June 11, 2036 Option expiration for this grant

Underlying shares 10,000 shares Common stock underlying the option grant

Post-grant derivative holdings 10,000 options Total options held directly after this acquisition

Key Terms

Stock Option (right to buy), exercise price, change in control, vest in full, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

exercise price financial

"conversion_or_exercise_price: 2.0300"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

change in control financial

"will become exercisable in full upon a change in control of the issuer"

A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.

vest in full financial

"This option will vest in full on the earlier of the first anniversary"

grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Grossman Jessica D.

(Last) (First) (Middle)

3655 NOBEL DRIVE

SUITE 260

(Street)

SAN DIEGO CALIFORNIA 92122

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Dare Bioscience, Inc. [ DARE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$2.03	06/11/2026		A		10,000		(1)	06/11/2036	Common stock	10,000	$0	10,000	D

Explanation of Responses:

1. This option will vest in full on the earlier of the first anniversary of the grant date or immediately prior to the issuer's first annual meeting of stockholders occurring after the grant date, subject to the director's continued service as a director, and will become exercisable in full upon a change in control of the issuer.

Remarks:

	/s/ Sabrina Martucci Johnson, Attorney-in-fact	06/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Dare Bioscience (DARE) report for Jessica D. Grossman?

Dare Bioscience reported that director Jessica D. Grossman received a grant of stock options for 10,000 shares of common stock. These options are a compensation-related award, not an open-market stock purchase or sale, and are exercisable at $2.03 per share.

What is the exercise price of the new Dare Bioscience (DARE) stock options?

The newly granted stock options to director Jessica D. Grossman have an exercise price of $2.03 per share. This means she can buy Dare Bioscience common stock at $2.03 once the options vest and become exercisable, subject to the award’s terms.

How many Dare Bioscience (DARE) options does Jessica D. Grossman hold after this grant?

After this transaction, Jessica D. Grossman holds 10,000 stock options directly. All of these options relate to Dare Bioscience common stock and were acquired in a single grant, according to the Form 4 insider filing data provided.

When do the Dare Bioscience (DARE) options granted to Jessica D. Grossman vest?

The option will vest in full on the earlier of the first anniversary of the grant date or immediately before Dare Bioscience’s first annual stockholder meeting after the grant date. Vesting is conditioned on her continued service as a director during this period.

When do Jessica D. Grossman’s Dare Bioscience (DARE) stock options expire?

The stock options granted to Jessica D. Grossman expire on June 11, 2036. After that expiration date, any unexercised options will lapse, and she will no longer be able to purchase Dare Bioscience common stock under this particular grant.

What happens to the Dare Bioscience (DARE) options if there is a change in control?

The options become fully exercisable upon a change in control of Dare Bioscience. This means that if the company undergoes a qualifying change in control event, the entire 10,000-share option grant can be exercised regardless of the normal vesting schedule.